IRRAS Geçmiş Kazanç Performansı

Hala bu şirketin son kazanç raporunu inceliyoruz

Geçmiş kriter kontrolleri 0/6

IRRAS şirketinin kazançları yıllık ortalama -6.1% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 1.1% oranında azalan oldu. Gelirler yıllık ortalama 47.2% oranında artan oldu.

Anahtar bilgiler

-6.1%

Kazanç büyüme oranı

38.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	4.3%
Gelir büyüme oranı	47.2%
Özkaynak getirisi	-455.7%
Net Marj	-455.7%
Sonraki Kazanç Güncellemesi	21 Feb 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

IRRAS nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:4Z7 Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 23	43	-196	153	49
31 Mar 23	43	-193	145	52
31 Dec 22	40	-167	130	46
30 Sep 22	37	-164	120	39
30 Jun 22	32	-141	106	29
31 Mar 22	27	-131	101	24
31 Dec 21	22	-136	93	24
30 Sep 21	18	-131	90	27
30 Jun 21	14	-135	88	29
31 Mar 21	10	-140	87	28
31 Dec 20	7	-136	90	29
30 Sep 20	8	-134	88	28
30 Jun 20	7	-139	87	26
31 Mar 20	7	-147	90	28
31 Dec 19	5	-151	89	30
30 Sep 19	2	-165	102	28
30 Jun 19	1	-171	111	30
31 Mar 19	0	-160	108	29
31 Dec 18	6	-139	103	24
30 Sep 18	7	-112	83	26
30 Jun 18	18	-78	72	17
31 Mar 18	18	-67	66	15
31 Dec 17	12	-61	56	13
30 Sep 17	11	-48	48	7
31 Dec 16	0	-32	27	3
31 Dec 15	0	-13	7	4

Kaliteli Kazançlar: 4Z7 şu anda kârlı değil.

Büyüyen Kar Marjı: 4Z7 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4Z7 kârlı değildir ve zararlar son 5 yılda yılda 6.1% oranında artmıştır.

Büyüme Hızlandırma: 4Z7 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4Z7 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 10.1% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4Z7 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -455.69% ) sahiptir.

IRRAS Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin